Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Purchased by Boothbay Fund Management LLC

Boothbay Fund Management LLC raised its stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 24.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 693,693 shares of the company's stock after buying an additional 136,264 shares during the period. Boothbay Fund Management LLC owned about 1.55% of Y-mAbs Therapeutics worth $5,432,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. KLP Kapitalforvaltning AS purchased a new position in shares of Y-mAbs Therapeutics during the 4th quarter valued at approximately $46,000. Wells Fargo & Company MN increased its holdings in Y-mAbs Therapeutics by 54.1% in the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company's stock valued at $137,000 after buying an additional 6,131 shares in the last quarter. SG Americas Securities LLC raised its position in shares of Y-mAbs Therapeutics by 30.7% in the fourth quarter. SG Americas Securities LLC now owns 17,729 shares of the company's stock worth $139,000 after acquiring an additional 4,163 shares during the period. XTX Topco Ltd boosted its stake in shares of Y-mAbs Therapeutics by 83.8% during the 4th quarter. XTX Topco Ltd now owns 20,768 shares of the company's stock worth $163,000 after acquiring an additional 9,468 shares in the last quarter. Finally, Principal Financial Group Inc. grew its position in shares of Y-mAbs Therapeutics by 9.4% during the 4th quarter. Principal Financial Group Inc. now owns 22,197 shares of the company's stock valued at $174,000 after acquiring an additional 1,903 shares during the period. Institutional investors and hedge funds own 70.85% of the company's stock.

Y-mAbs Therapeutics Stock Performance

Shares of NASDAQ:YMAB traded up $0.28 during trading hours on Friday, reaching $4.39. The stock had a trading volume of 62,688 shares, compared to its average volume of 325,573. Y-mAbs Therapeutics, Inc. has a 1 year low of $3.84 and a 1 year high of $17.78. The stock has a market capitalization of $198.51 million, a price-to-earnings ratio of -8.10 and a beta of 0.71. The firm's 50 day moving average is $4.73 and its 200-day moving average is $7.91.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). The company had revenue of $26.50 million for the quarter, compared to analyst estimates of $26.70 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period in the previous year, the business posted ($0.02) EPS. Analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current year.

Analyst Ratings Changes

YMAB has been the topic of a number of recent analyst reports. Wedbush reiterated an "outperform" rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. HC Wainwright cut their price target on Y-mAbs Therapeutics from $22.00 to $12.00 and set a "buy" rating for the company in a report on Friday, March 21st. Bank of America downgraded shares of Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 target price on the stock. in a research note on Tuesday, April 22nd. Morgan Stanley decreased their price target on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a research note on Wednesday, March 5th. Finally, Truist Financial dropped their target price on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a "buy" rating for the company in a report on Wednesday, March 5th. Two research analysts have rated the stock with a sell rating, seven have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $17.40.

Insider Buying and Selling

In related news, insider Thomas Gad sold 10,810 shares of Y-mAbs Therapeutics stock in a transaction on Friday, March 7th. The shares were sold at an average price of $5.23, for a total value of $56,536.30. Following the transaction, the insider now directly owns 202,721 shares in the company, valued at $1,060,230.83. This trade represents a 5.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 22.50% of the stock is currently owned by company insiders.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.